Legislative Oversight Of Device Third-Party Review Likely, Staffers Tell FDLI
This article was originally published in The Gray Sheet
Executive Summary
Broader support on Capitol Hill to modify FDA's third-party review program in a way that would encourage greater utilization may hinge on members of Congress backing away from the larger issue of privatizing the agency.